GlassScriptPhysician profile
Sean Duke
NPI 1437619178
$1,359.75
in general payments reported to CMS, 2019-2025
24 companies · $312 in 2025
The $312 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $11.79 · 2021: $233 · 2022: $445 · 2023: $231 · 2024: $126 · 2025: $312.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $670.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $669.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $215.01 | 2022-2025 | Mavenclad |
| Genzyme Corporation | $170.24 | 2021-2023 | |
| Alexion Pharmaceuticals, INC. | $142.54 | 2021-2025 | Ultomiris |
| Penumbra, INC. | $126.47 | 2024 | Penumbra System |
| Astrazeneca Pharmaceuticals LP | $86.46 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $71.77 | 2022-2023 | Gammagard |
| Biohaven Pharmaceutical Holding Company LTD. | $55.07 | 2022 | |
| Ucb, INC. | $47.10 | 2025 | Fintepla, Nayzilam |
| Horizon Therapeutics Plc | $44.07 | 2022 | |
| Lilly USA, LLC | $40.88 | 2023 | Emgality, Reyvow, Amyvid |
| Pfizer INC. | $39.94 | 2025 | |
| Ani Pharmaceuticals, INC. | $39.13 | 2025 | Purified Cortrophin Gel |
| Novartis Pharmaceuticals Corporation | $34.81 | 2023 | |
| Biohaven Pharmaceuticals, INC. | $31.74 | 2021 | |
| Medtronic, INC. | $31.06 | 2025 | Linq II |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $29.32 | 2025 | Vyepti |
| Genentech USA, INC. | $28.11 | 2022-2023 | Ocrevus, Enspryng |
| Averitas Pharma INC. | $24.08 | 2023 | Qutenza |
| Eisai INC. | $21.05 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $18.59 | 2025 | Ajovy |
| Biogen, INC. | $17.37 | 2022 | |
| Celgene Corporation | $16.60 | 2021 | |
| Abbvie INC. | $16.55 | 2025 | |
| Avanir Pharmaceuticals, INC. | $11.79 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Duke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.